Mr. Stephen Van Deventer reports

BIOGENE THERAPEUTICS WELCOMES EX PFIZER AND MODERNA SENIOR LEADERSHIP DR. BARRY TICHO

Preveceutical Medical Inc.'s wholly owned subsidiary, BioGene Therapeutics Inc., has appointed Dr. Barry Ticho, MD, PhD, to the scientific advisory board effective on Dec. 1, 2024.

Stephen Van Deventer, chief executive officer of BioGene, commented:

"We are honoured to welcome Dr. Barry Ticho, MD, PhD, to our scientific advisory board. Barry's extensive leadership in drug development and biopharma, coupled with his entrepreneurial spirit, will bring unparalleled insight to BioGene's mission to deliver innovative therapies. His deep expertise in advancing groundbreaking treatments across neurology, ophthalmology, cardiovascular and metabolic diseases perfectly aligns with our focus areas, and we look forward to his contributions to our scientific and strategic initiatives."

Dr. Barry Ticho's career highlights:

Dr. Ticho is a physician-scientist and entrepreneur with over 25 years of biopharma and drug development expertise. Currently serving as chief medical officer at Stoke Therapeutics (Nasdaq: STOK), Dr. Ticho has played a pivotal role in transforming Stoke from a private company with nine employees to a publicly traded organization with more than 100 employees and clinical programs targeting severe genetic diseases in neurology and ophthalmology.

Dr. Ticho also co-founded Verve Therapeutics and served as its first chief executive officer, pioneering a novel gene-editing approach to prevent cardiovascular disease. Under his leadership, Verve Therapeutics laid the foundation for its public offering in 2021 (Nasdaq: VERV). Prior to these roles, Dr. Ticho led R&D (research and development) initiatives for cardiovascular and metabolic diseases at Moderna Therapeutics, and he has held senior leadership positions at Pfizer and Biogen, where he directed groundbreaking programs in heart failure, multiple sclerosis and Alzheimer's disease.

Dr. Ticho's academic and advisory contributions are equally impressive. He serves on the scientific advisory boards for Cardior Pharmaceuticals, Mana.bio and Sania, as well as the board of advisers for the Museum of Science in Boston, where he champions science education and community outreach. A passionate advocate for science and innovation, Dr. Ticho has inspired new generations of scientists through his work.

Dr. Ticho earned his MD and PhD from the University of Chicago and completed his pediatrics training at Northwestern University, followed by a cardiology fellowship at Boston Children's Hospital. He has also held clinical staff positions at Harvard Medical School and Massachusetts General Hospital.

Dr. Ticho remarked on his appointment:

"I am delighted to join BioGene's scientific advisory board and collaborate with a team deeply committed to advancing transformative therapies. BioGene's focus on addressing critical unmet medical needs aligns with my professional passion for innovation and patient-centred solutions. I look forward to contributing to the company's exciting future."

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies, utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

About BioGene Therapeutics Inc.

BioGene Therapeutics is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5-per-cent R&D tax cash-back incentive. This subsidiary supports continuing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

We seek Safe Harbor.